azenosertib + pegylated liposomal doxorubicin

Azenosertib + pegylated liposomal doxorubicin is a **combination regimen** under clinical investigation for cancer treatment, primarily ovarian cancer. Azenosertib is a small molecule inhibitor targeting WEE1, a DNA damage response kinase involved in cell cycle regulation. By inhibiting WEE1, azenosertib prevents phosphorylation and inactivation of Cyclin/CDK complexes, forcing cancer cells with unrepaired DNA into mitosis, resulting in replication stress, mitotic catastrophe, and apoptosis[1]. Pegylated liposomal doxorubicin is a liposome-encapsulated formulation of the anthracycline doxorubicin, which intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptotic cell death. The combination is being studied for potential synergy in inducing cancer cell death through complementary DNA-damaging and cell cycle checkpoint-disrupting mechanisms, particularly in ovarian cancer and other solid tumors[2].

Other names

ZN-c3 + pegylated liposomal doxorubicin